On January 15, 2017, noted cancer immunotherapy expert Jedd D. Wolchok, M.D., Ph.D. explored the latest developments in the field across a variety of cancers, including melanoma, lung cancer, head and neck cancer, bladder cancer, and hodgkin lymphoma, and look ahead to the anticipated clinical trial data readouts in 2017. Cancer immunotherapy is one of the most promising new approaches to treating cancer patients today.
Dr. Wolchok is chief of the Melanoma and Immunotherapeutics Service and director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center (MSKCC); an associate director of the Ludwig Center for Cancer Immunotherapy at MSKCC, an associate member of Ludwig Cancer Research, and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at MSKCC. He is director of the CRI/Ludwig Clinical Trials Network, and is an associate director of the Cancer Research Institute Scientific Advisory Council.
This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This series is presented by Bristol-Myers Squibb and Genentech. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.